Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
P52434
UPID:
RPAB3_HUMAN
Alternative names:
DNA-directed RNA polymerase II subunit H; DNA-directed RNA polymerases I, II, and III 17.1 kDa polypeptide; RPB17; RPB8 homolog
Alternative UPACC:
P52434; C9J413; C9JBJ6; C9JCU7; C9JUA8; P53802; Q969R0
Background:
DNA-directed RNA polymerases I, II, and III subunit RPABC3, also known as DNA-directed RNA polymerase II subunit H, plays a pivotal role in the transcription of DNA into RNA, utilizing ribonucleoside triphosphates. It is a common component of RNA polymerases I, II, and III, which are essential for synthesizing ribosomal RNA precursors, mRNA precursors, functional non-coding RNAs, and small RNAs such as 5S rRNA and tRNAs.
Therapeutic significance:
Understanding the role of DNA-directed RNA polymerases I, II, and III subunit RPABC3 could open doors to potential therapeutic strategies.